Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-20 of 138
Keywords: Acute myeloid leukemia
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
Journal Articles
Ring Chromosomes in Patients with Myeloid Neoplasms Are Associated with a Poor Response to Therapy
Open AccessDaniel I. Nathan, Ronald Hoffman, Daiva Ahire, John Mascarenhas, Bridget K. Marcellino, Douglas Tremblay, Lewis R. Silverman, Vesna Najfeld, Jonathan Feld
Journal:
Acta Haematologica
Acta Haematol (2025)
Published Online: 12 June 2025
.... Myeloid malignancy gene mutational status in MN patients with RC. AML, acute myeloid leukemia; Chemo, chemotherapy; HMA, hypomethylating agent; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; VEN, venetoclax; VUS, variant of unknown significance. Table 1. Demographic...
Journal Articles
Karin Mayer, Leonie Birk, Katjana Schwab, Ingo G.H. Schmidt-Wolf, Marie von Lilienfeld-Toal, Peter Brossart, Axel Glasmacher, Corinna Hahn-Ast
Journal:
Acta Haematologica
Acta Haematol (2025)
Published Online: 05 May 2025
...Karin Mayer; Leonie Birk; Katjana Schwab; Ingo G.H. Schmidt-Wolf; Marie von Lilienfeld-Toal; Peter Brossart; Axel Glasmacher; Corinna Hahn-Ast Introduction: The standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) is 7 days cytarabine and 3 days daunorubicin. However...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2025)
Published Online: 08 April 2025
...Jason S. Gilbert; Daniel A. Pollyea; Thomas J. Walsh; Andreas H. Groll; Hillard M. Lazarus Background: The advent of molecularly cloned hematopoietic growth factors (rhuG-CSF and rhuGM-CSF) enhanced the safety in treating acute myeloid leukemia (AML) by reducing the duration of neutropenia and thus...
Journal Articles
Efficacy of Haploidentical Allogeneic Hematopoietic Cell Transplantation following Two Courses of Venetoclax and Azacytidine Therapy in Patients over 55 Years Old with Acute Myelogenous Leukemia
Available to PurchaseJunjie Cao, Xianxu Zhuang, Danjie Luo, Renzhi Pei, Ying Lu, Dong Chen, Shuangyue Li, Xiaohong Du, Xuhui Liu
Journal:
Acta Haematologica
Acta Haematol 427–436.
Published Online: 25 October 2024
...Junjie Cao; Xianxu Zhuang; Danjie Luo; Renzhi Pei; Ying Lu; Dong Chen; Shuangyue Li; Xiaohong Du; Xuhui Liu Introduction: The combination of venetoclax (VEN) and azacytidine (AZA) has demonstrated potential in achieving rapid and effective remissions in elderly patients with acute myeloid leukemia...
Journal Articles
Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial
Available to PurchaseJennifer Marvin-Peek, Valerie Shelton, Kelly Brassil, Bryan Fellman, Austin Barr, Kelly Sharon Chien, Danielle Hammond, Mahesh Swaminathan, Nitin Jain, William Wierda, Alessandra Ferrajoli, Courtney DiNardo
Journal:
Acta Haematologica
Acta Haematol (2025) 148 (2): 233–243.
Published Online: 11 June 2024
... and treatment adherence in patients with cancer. We report the outcomes of a pilot trial of a digital health coach intervention in patients with leukemia with the aim of improving self-efficacy. Methods: Adult patients with newly diagnosed acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) were...
Journal Articles
Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada
Available to PurchaseJean Lachaine, Catherine Beauchemin, Fatéma Dodat, Yunghan Au, William K. Evans, Brian Leber, Kristjan Paulson, Andre Schuh, John Storring
Journal:
Acta Haematologica
Acta Haematol (2025) 148 (1): 8–21.
Published Online: 21 February 2024
...Jean Lachaine; Catherine Beauchemin; Fatéma Dodat; Yunghan Au; William K. Evans; Brian Leber; Kristjan Paulson; Andre Schuh; John Storring Introduction: Acute myeloid leukemia (AML) represents a significant burden for patients and their families, and to the healthcare system. This study estimated...
Journal Articles
Prevalence, Risk Factors, and Prognostic Value of Anxiety and Depression in Acute Myeloid Leukemia
Open Access
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (5): 576–586.
Published Online: 16 February 2024
...Tao Zhong; Dan Xu; Wenchao Li Introduction: Limited studies report anxiety and depression prevalence and their correlations with prognosis in acute myeloid leukemia (AML). Even worse, their risk factors for AML remained unclear. This study aimed to investigate the prevalence, risk factors...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (2): 229–246.
Published Online: 16 February 2024
...Franziska Wachter; Yana Pikman Background: Acute myeloid leukemia (AML) is a biologically heterogenous disease arising in clonally proliferating hematopoietic stem cells. Sequential acquisition of mutations leads to expanded proliferation of clonal myeloid progenitors and failure of differentiation...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (2): 122–132.
Published Online: 08 December 2023
...Karen-Sue Carlson; Ashley Cunningham; Maximilian Stahl; Eric Winer; Laura C. Michaelis Background: The classification of acute myeloid leukemia (AML) has long been overseen by the World Health Organization (WHO) and published into a series of “Blue Books.” These ledgers serve as the reference...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (2): 175–185.
Published Online: 05 December 2023
...Jeremy DiGennaro; David A. Sallman Background: Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy characterized by uncontrolled proliferation and impaired differentiation of myeloid cells in the bone marrow. The tumor suppressor gene TP53 plays a crucial role in maintaining...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (2): 219–228.
Published Online: 30 November 2023
...Justin D. Woods; Heidi D. Klepin Background: Acute myeloid leukemia (AML) is a heterogenous disease that affects mostly older adults with varying baseline health and functional status. Treatment options have expanded for older adults, ranging from less intensive chronic therapies to intensive...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (2): 133–146.
Published Online: 30 November 2023
...Amanda L. Blackmon; Christopher S. Hourigan Background: Measurable residual disease (MRD) test positivity during and after treatment in patients with acute myeloid leukemia (AML) has been associated with higher rates of relapse and worse overall survival. Current approaches for MRD testing...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (2): 119–121.
Published Online: 30 November 2023
..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Acute myeloid leukemia Novel therapies Measurable residual disease TP53...
Journal Articles
Emily A. Cowen, Dulce M. Barrios, Melissa P. Pulitzer, Andrea P. Moy, Stephen W. Dusza, Susan De Wolf, Mark B. Geyer, Alina Markova
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (4): 457–464.
Published Online: 21 November 2023
... therapies for acute myeloid leukemia (AML) have not yet been described. Methods: Through retrospective review of 19,432 patients diagnosed with acute/chronic leukemia or myelodysplastic syndromes/myeloproliferative neoplasms (MDS+/−MPN) over 28 years, we calculated the incidence of SS in the setting...
Journal Articles
Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways
Available to Purchase
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (3): 310–324.
Published Online: 03 November 2023
...Mu-Nan Zhao; Long Su; Fei Song; Zhi-Feng Wei; Tian-Xue Qin; Yun-Wei Zhang; Wei Li; Su-Jun Gao Introduction: Acute myeloid leukemia (AML) with internal tandem duplication (ITD) mutations in Fms-like tyrosine kinase 3 (FLT3) has an unfavorable prognosis. Recently, using newly emerging inhibitors...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (2): 159–174.
Published Online: 31 October 2023
...Shira Buchrits; Ofir Wolach Background: Relapsed or refractory (R/R) acute myeloid leukemia (AML) is a challenging, high-risk, clinical scenario with a dismal outcome. Recent insights on the genetic, epigenetic, and metabolic events that drive clonal progression and the advent of novel therapies...
Journal Articles
Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation
Available to PurchaseLia Minculescu, Joanne Reekie, Soeren Lykke Petersen, Brian Thomas Kornblit, Ida Schjoedt, Niels Smedegaard Andersen, Lisbeth Pernille Andersen, Anne Fischer-Nielsen, Eva Kannik Haastrup, Lone Smidstrup Friis, Henrik Sengelov
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (3): 325–332.
Published Online: 12 October 2023
.... The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Acute myeloid leukemia Allogeneic hematopoietic stem cell transplantation Donor lymphocyte...
Journal Articles
Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012 to 2022
Available to PurchaseDahniel Sastow, Grace Van Hyfte, Jonathan Feld, Marina Kremyanskaya, John Mascarenhas, Douglas Tremblay
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (3): 292–299.
Published Online: 26 September 2023
...Dahniel Sastow; Grace Van Hyfte; Jonathan Feld; Marina Kremyanskaya; John Mascarenhas; Douglas Tremblay Introduction: Central nervous system (CNS) involvement in acute myeloid leukemia (AML) can be successfully treated with intrathecal chemotherapy and carries debatable prognostic impact. However...
Journal Articles
Limited Efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse
Available to Purchase
Journal:
Acta Haematologica
Acta Haematol (2024) 147 (3): 352–359.
Published Online: 26 September 2023
...Soyoung Bae; Seungwon Sa; Silvia Park; Byung-Sik Cho; Hee-Je Kim The recently approved BCL2 inhibitor venetoclax (VEN) has achieved promising outcomes in new and relapsed/refractory (R/R) acute myeloid leukemia (AML). Although its use is not well established in R/R AML with extramedullary disease...
Journal Articles
Cladribine, Cytarabine, and Etoposide-Based Regimens Are Safe and Tolerable In Relapsed and Refractory Acute Myeloid Leukemia Patients
Available to Purchase
Journal:
Acta Haematologica
Acta Haematol (2023) 146 (6): 540–545.
Published Online: 14 September 2023
...Jose Tinajero; Dat Ngo; Amandeep Salhotra; Paul Koller Intensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analog. In patients who cannot tolerate an anthracycline due to comorbidities, one...
1